Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma

Baldeep Wirk, Timothy S. Fenske, Mehdi Hamadani, Mei Jie Zhang, Zhen Huan Hu, Görgün Akpek, Mahmoud D. Aljurf, Philippe Armand, Ernesto Ayala, Veronika Bachanova, Brian Bolwell, Mitchell S. Cairo, Amanda Cashen, Yi Bin Chen, Luciano J. Costa, Shatha Farhan, César O. Freytes, James L. Gajewski, John Gibson, Gregory A. HaleLeona A. Holmberg, Jack W. Hsu, David J. Inwards, Rummurti T. Kamble, Dipnarine Maharaj, Richard T. Maziarz, Reinhold Munker, Rajneesh Nath, Nishitha M. Reddy, Craig B. Reeder, David A. Rizzieri, Craig S. Sauter, Bipin N. Savani, Harry C. Schouten, Anna Sureda, Julie M. Vose, Edmund K. Waller, Peter H. Wiernik, Robert Peter Gale, Linda J. Burns, Wael Saber

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


There are limited data on the outcomes of autologous or allogeneic hematopoietic cell transplantation (HCT) in diffuse large B cell lymphoma transformed from follicular lymphoma. We analyzed transplantation outcomes in 141 subjects with biopsy-proven diffuse large B-cell lymphoma transformed from follicular lymphoma reported to the Center for International Blood and Marrow Transplant Research between 1990 and 2009. Two groups were identified: autologous HCT (auto-HCT; n = 108) and allogeneic HCT (allo-HCT; n = 33). Fewer auto-HCTs were done for transformed follicular lymphoma in 2003 to 2009, with a shift favoring allo-HCT. Auto-HCT was associated with a 1-year nonrelapse mortality (NRM) of 8% (95% confidence interval [CI], 4% to 14%), 5-year progression-free survival of 35% (95% CI, 26% to 45%), and 5-year overall survival of 50% (95% CI, 40% to 59%). In contrast, allo-HCT was associated with a 1-year NRM of 41% (95% CI, 23% to 58%), 5-year progression-free survival of 18% (95% CI, 6% to 35%), and 5-year overall survival of 22% (95% CI, 8% to 41%). Auto-HCT for transformed follicular lymphoma achieves sustained remission in a high proportion of subjects. The high NRM of allo-HCT offset any benefit that might be associated with this transplantation modality.

Original languageEnglish (US)
Pages (from-to)951-959
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Issue number7
StatePublished - Jul 2014


  • Transformed follicular lymphoma
  • Transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma'. Together they form a unique fingerprint.

Cite this